← Back to Search

Other

Ketone Supplements for Cerebral Health (kCBF Trial)

N/A
Recruiting
Led By Jeremy J Walsh, PhD
Research Sponsored by McMaster University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Between the ages of 18 and 35
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2-hour, then during submaximal exercise (performed after 2-hour rest period)
Awards & highlights

kCBF Trial Summary

This trial aims to find out if taking oral ketone supplements can improve cognition, cerebral blood flow, and exercise performance.

Who is the study for?
This trial is for young adults aged 18 to 35 who are generally healthy. It's not suitable for individuals with obesity, type 2 diabetes, a history of serious heart conditions or concussions with ongoing symptoms, or those currently on a ketogenic diet or taking ketone supplements.Check my eligibility
What is being tested?
The study tests the effects of two different doses of an oral ketone supplement on brain blood flow and thinking skills in young adults. Participants will receive either a placebo, low dose β-OHB (a type of ketone), or high dose β-OHB to see how these affect their bodies and minds.See study design
What are the potential side effects?
Potential side effects may include changes in blood acidity which could impact exercise performance if taken shortly before physical activity. Other side effects are not specified but could relate to typical reactions from dietary supplements.

kCBF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 35 years old.

kCBF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2-hour, then during submaximal exercise (performed after 2-hour rest period)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2-hour, then during submaximal exercise (performed after 2-hour rest period) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Resting cerebral blood flow (CBF)
Secondary outcome measures
Brain-derived neurotrophic factor (BDNF)
Cognitive Function
End-tidal CO2
+3 more

kCBF Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Low Dose β-OHBExperimental Treatment1 Intervention
Single dose of a ketone monoester ([R]-3-hydroxybutyl [R]-3-hydroxybutyrate; 0.3 g β-OHB/kg body weight)
Group II: High Dose β-OHBExperimental Treatment1 Intervention
Single dose of a ketone monoester ([R]-3-hydroxybutyl [R]-3-hydroxybutyrate; 0.6 g β-OHB/kg body weight)
Group III: PlaceboPlacebo Group1 Intervention
Single dose of a taste-matched calorie-free placebo

Find a Location

Who is running the clinical trial?

McMaster UniversityLead Sponsor
880 Previous Clinical Trials
2,597,808 Total Patients Enrolled
1 Trials studying Cognition
30 Patients Enrolled for Cognition
Jeremy J Walsh, PhDPrincipal InvestigatorMcMaster University
1 Previous Clinical Trials
20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still enrollment opportunities for this clinical experiment?

"As per the information available on clinicaltrials.gov, this medical trial is not accepting any new candidates at present. It was first posted in October 1st 2023 and last updated September 8th 2023. Nevertheless, there are 36 other trials that are actively recruiting participants now."

Answered by AI

Is the cut-off age for this trial under 75 years of age?

"This clinical trial is offered to patients between the ages of 18 and 35. There are other 5 trials available for those under 18, while 24 medical studies target individuals over 65 years old."

Answered by AI

Are there any eligibility requirements for volunteers in this research?

"This medical experiment requires participants to be of age and have cognitive aptitude. The study will accept a maximum of 20 individuals, aged 18-35 years old."

Answered by AI
~0 spots leftby May 2024